Torrent Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations

Torrente Pharmaceuticals (NSE:TORNTPHARM) Third quarter 2024 results

Key financial results

  • Revenue: Rs 27 billion (an increase of 8.4% from Q3 2023).
  • Net income: Rs 4.43 billion (an increase of 56% from Q3 2023).
  • Profit margin: 16% (vs. 11% in Q3 2023). The margin increase was driven by higher revenues.
  • EPS: ₹ 13.10 (up from ₹ 8.36 in Q3 2023).
NSEI:TORNTPHARM Revenue and Earnings Growth February 4, 2024

All figures shown in the table above correspond to the period of the last 12 months (TTM)

Torrent Pharmaceuticals EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) beat analyst estimates by 4.7%.

Looking ahead, revenue is projected to grow 11% annually on average over the next 3 years, compared to a projected 10% growth for the pharmaceutical industry in India.

Performance of the Indian pharmaceutical industry.

The company's shares are up 2.1% compared to a week ago.

Risk analysis

Be aware of Torrent Pharmaceuticals is showing 2 warning signs in our investment analysis What you should know about...

Valuation is complex, but we are helping to simplify it.

Find out if Torrente Pharmaceuticals is potentially overvalued or undervalued by checking out our full analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

See the free analysis

This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts using only unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell shares and does not take into account your objectives or financial situation. Our goal is to provide you with focused, long-term analysis driven by fundamental data. Please note that our analysis may not take into account the latest announcements from price-sensitive companies or qualitative material. Simply Wall St has no position in any of the stocks mentioned.

Leave a Comment

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *